Cipla Limited – Q4 FY26 Results

key financial highlights

• Revenue from Operations:
  • Revenue (Q4 FY26): ₹6,541.20 Cr
    • QoQ Change: -7.54%
    • YoY Change: -2.80%
  • Previous Quarter (Q3 FY26): ₹7,074.48 Cr
  • Previous Year (Q4 FY25): ₹6,729.69 Cr
• Profit After Tax (PAT):
  • PAT (Q4 FY26): ₹542.51 Cr
    • QoQ Change: -19.54%
    • YoY Change: -55.32%
  • Previous Quarter (Q3 FY26): ₹674.25 Cr
  • Previous Year (Q4 FY25): ₹1,214.14 Cr
• QoQ Performance:
  • Revenue: Negative
  • Profit: Strongly Positive

Margin Analysis

Drivers:

• Employee benefit expenses increased materially
• Other operating expenses remained elevated
• Impairment charge relating to investment in associates impacted earnings
• Revenue decline reduced operating leverage benefits
• Higher depreciation and amortisation expenses affected margins

Insight:

• Margins compressed significantly as expense growth outpaced revenue generation during the quarter.

Segment insight

Business Summary:

Cipla continues operating as a diversified pharmaceutical company with strong exposure across domestic formulations, respiratory therapies, branded generics, and international markets.

Key Characteristics:

• Strong domestic pharmaceutical franchise
• Global generics exposure
• High regulatory dependency
• R&D-driven business model
• Margin-sensitive to product mix and compliance costs

Earning quality check

Key Drivers:

• Operating cash flow remained healthy at ₹3,940.02 Cr
• PAT weakened materially despite stable annual revenue growth
• Working capital adjustments impacted operational efficiency
• Higher impairment and operating costs affected earnings conversion
• Cash reserves and investments strengthened balance sheet quality

Interpretations:

• Earnings quality remains moderate. While cash generation stayed stable, profitability compression and impairment charges weakened overall earnings strength.

balance sheet Analysis

• Total Assets: ₹42,495.98 Cr
• Total Liabilities: ₹7,975.74 Cr

Insight:

• Equity increased strongly to ₹34,520.24 Cr
• Cash and cash equivalents rose to ₹1,018.22 Cr
• Investments increased to ₹7,679.42 Cr
• Borrowings remained extremely low relative to balance sheet size
• Overall leverage profile stayed highly conservative

Cash flow analysis

Operating Cash Flow:

• Net Cash Generated from Operating Activities : ₹3,940.02 Cr
• Operating cash flow remained strong though lower than FY25 due to profitability moderation and working capital changes.

Investing Cash Flow:

• Net Cash Used in Investing Activities : ₹2,326.13 Cr
• Key Observations:
  • Continued investment in property, plant, and equipment
  • Higher investment into intangible assets and acquisitions
  • Increase in treasury and investment deployment activities

Financing Cash Flow:

• Net Cash Used in Financing Activities : ₹1,233.65 Cr
• Key Observations:
  • Dividend payout remained significant
  • Borrowing levels stayed low
  • Financing structure continued conservative

key risks

• Pricing pressure in global generic markets
• Regulatory and compliance risks
• Currency fluctuation exposure
• Margin pressure from rising operational costs
• Product concentration and competitive intensity

management strategy signals

Focus Area:

• Expanding global pharmaceutical presence
• Strengthening respiratory and specialty portfolio
• Enhancing R&D capabilities
• Maintaining strong cash generation
• Strategic investment allocation and operational efficiency

Financial metrics table

Quarterly Performance Context